VC activity is booming in the healthcare sector. Point in case, investments have reached record-breaking numbers, including in the AI/ML field. This panel will discuss the future of the investment sector, how investments in AI/ML are shaping healthcare, and what to expect in the years to come.
Greg Yap is a partner at Menlo Ventures, where he leads life science and digital health investing. Recent investments include Clear Labs, Epiodyne, Pliant Therapeutics, and Senti Biosciences. Prior to Menlo, Greg served as entrepreneur-in-residence at Illumina Ventures, where he focused on new genomics investments. Previously, Greg was CEO and cofounder of Biodesy, a next generation protein analysis company, and CEO and cofounder of PyrAmes, a digital health remote monitoring company. Greg also led Roche Diagnostics/Ventana’s global market-leading cancer assay business, serving 20 million patients and delivering $500 million revenue per year. His operating experience also includes: GE’s first healthcare entrepreneur-in-residence; chief operating officer at Cellpoint Diagnostics, an early liquid biopsy startup; vice president and general manager for genetics and molecular diagnostics at Affymetrix; and consultant for McKinsey & Company. Greg received his AB in molecular biology from Princeton University and his MBA from Stanford Graduate School of Business.
Nan Li is a Managing Director at Obvious Ventures, a venture capital firm investing in entrepreneurs reimagining every sector of the global economy. Nan leads the firm’s investments in companies harnessing deep tech to transform legacy industries like pharmaceuticals, protein therapy, industrial materials, and manufacturing. His investments include Recursion Pharmaceuticals, LabGenius, DarwinAI, Octave Health, Zymergen, and Planet. Prior to joining Obvious, Nan managed early-stage tech investments for Eric Schmidt's Innovation Endeavors and led Product, Operations, and Finance at Gigwalk - a mobile crowdsourced data and analytics company funded by Greylock Partners and August Capital. Nan was also a VC at Bain Capital Ventures, a management consultant at Bain & Company, and a Product Manager at Microsoft. He is an adjunct at Stanford University, lecturing on Applied Symbolic Systems in Venture Capital & Entrepreneurship.
Vineeta is a physician-scientist and life science investor. For the past five years, she invested with GV (Google Ventures) in companies including Maze Therapeutics, Arrakis Therapeutics, and Locana. Previously, she was a Director of Product Management at Flatiron Health, where she led development of national-scale databases which integrate clinical and genomic data for drug development and research in oncology. She has also been a computational researcher at the Broad Institute, and a management consultant for biotech, pharmaceutical, and medical device clients at McKinsey & Company in New York. Vineeta has a B.S. in biophysics from Stanford University, and earned M.D. and Ph.D. degrees from Harvard Medical School and MIT.